Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why would they want to get FDA approval which is not required for OTC supplement ?
Revenue reports will drive this more than other news IMO, looking for strong revenue growth in next quarterly.
Good to know, thanks!
FDA approval probably means they will need to go through trial, no? Unless there are existing trials in other markets they can reference.
You don’t have to look far to see where this is going if they RS. Just like the other company Anshu is running (yes Part Time CEO making hundreds of thousands per year both places). His other wonder stock mphase did a RS and very shortly tanked over 98%. By tanking that much the stock needs a 1000% gain to get to even. Same motto there too with unprofitable revenue. These companies are either scams or run by very incompetent people.
I was able to get out about 20% of my investment at $.02 but still just a wasted opportunity for them to build a legit business. One of the red flags for me was Anshu being part time CEO sharing duties and getting comp from another ticker. No legit CEO of decent size company will do that,’maybe if you’re operating a single site Dunkin’ Donuts.
Fool me once. a promising investment at one time, now typical greed by OTC management. I thought this company was different but it showed it’s true colors in 2020.
Too bad, this one had a lot of promise with Anshu as dealmaker and closing business. Problem was he was multitasking with another ticker he’s ceo and he was making unprofitable deals while taking nice bonuses he didn’t deserve.
Anshu screwed his angel investor who saved shareholders a year ago, now he needs Depends. Someone send him a box ??
https://www.depend.com/en-us/
Good perspective of what’s wrong, people keep thinking these new orders are good but if management is not being financially responsible they mean nothing. Toxic notes are just that - toxic. This one had so much promise as Anshu does seem to have capability to make deals and close sales, but he really screwed shareholders. I got 25% out between $.15 and $.025 but still left holding huge bag. And I heard him live on conference calls say he would be financially responsible and not dilute for growth. The other thing irking me is him taking in huge comp as part timer as shareholders get screwed. Sucks all the way around.
That’s because his comp his based on driving revenues and he seems intent on doing that disregarding any thought to shareholders the dam simp.
Per CC, late summer early fall for Interim MS results, Ralph said will be after 10 patients get all 3 treatments.
Positive MS phase 2 interim results will provide biggest short term boost followed by additional indication. $BCLI
The problem with this company is the CEO comp based on revenues he can still drive company and shareholders into ground by making bad deals just to drive revenue. Anshu’s Comp should be based on pps so his goals align to shareholders. And verus needs full time ceo. No wonder stock is in toilet, we have part time employee as ceo.
No debt and about $32M cash.
There she goes!!! Last call! $VRUS
There can’t be any uplist until pps is much higher to minimize R/S ratio (approx 1/100 at $.05 to get to $5) average trading needs to pick up as well unless uplist is when pps is $.10+ and ratio is less than 1/50.
What are you looking at? Must be one of your loser tickers.
Anshu is definitely deal maker. MLB, Marshall’s, TJ Max , etc she going to fly!! $VRUS
Last Call!!! $VRUS
Does anyone know terms of buyout?
New board members including Goldman Sachs executive, HE ALS and MS Phase 2 interim data coming, lookout above!!! $BCLI
There she goes!!! $VRUS
News!!! $VRUS Rolling thunder!!!
We are very excited today to announce that we have added a new subsidiary, ZC Top, in the biohazard mask space that I am sure investors find quite surprising. Being the actual manufacturer of the masks and HAZMAT suits is a real big deal! https://t.co/AHAc3jrn7x
— Verus Foods, Inc (@Verus_Foods) April 3, 2020
Agreed.
Markets reacting positively, going higher!
News!!!!!! $VRUS
Finally, the 10-K is wrapping up! We scheduled our call for the following Monday which will give us sufficient time to incorporate a presentation with the call and test this new platform. See PR for instructions... https://t.co/ZterWcOghR
— Verus Foods, Inc (@Verus_Foods) April 2, 2020
ALS phase 3 trial there are 3 doses of BCLI NurOwn stem cells given to patient, believe its 60-75 days between the doses (treatments)
Will be over $.02 in week or so, any thoughts over $.03 by end of April with good Fins? $VRUS
Yes of course, lots of signs where this is going: 1-last conference call stated “excited” to share ALS HE data in next 30-45 days, 2-recent $10M investment into company at $8/share with option to purchase more at $15, 3-“excited” to share MS phase 2 interim data expected next 30-45 days, 4-new indication to be announced. 5-Israeli govt approved 13 additional for ALS treatment on HE.
And it sounds like it will be this week possibly or early next week the latest as corporate tweet said by end of March so next Tuesday the latest. $VRUS
I thought it was strange though Chaim commented they are deciding if they should accept and treat the 13 new ones based on resources and priority’s. Why wouldn’t they want to treat the 13 under HE when they are getting paid for it?
Moral victory but glad we passed $.01
Doesn’t seem like partnership with Salesforce would make sense for the EDU distant learning market as SF is primarily a CRM app. A partnership with Cisco Webex, gotomeeting or Zoom would make more sense for EDU distant learning.
Extremely frustrated with this one, Anshu dropped ball and must now step up and get us current. This explanation of not being able to report financials because of CV travel restriction sounds suspicious to me - why can’t person participate via web conference or email docs? I’ve been a believer with all the positive moves they’ve made, ie getting their own mfg capability to improve margins to 40% etc so holding my 5.5M shares and see where this goes. Come on Anshu/$VRUS - Deliver!!
$BCLI Notes from call: 1) They are positioned perfectly with recent cash raises. 2) They made preparations for CV and plan to deliver on planned ALS and MS trial milestones. 3) They made arrangements with FDA to make adjustments for clinical sites to collect patients' information over the phone so patients don't have to travel to clinical sites. 4) FDA has agreed to all the company's suggestions for changes to FDA trial to have it move forward. 5) Company has raised $32M - $20M from ATM, $10M from investment at $8/share, $2.2M grant from CIRM. 6) Details from HE exemption clinical data and MS phase 2 data readouts will be out in next month or 2, mid-April - May. 7) New indications are being worked will be announced in next month or 2. 8) ALS trial is fully enrolled. Vast majority of patients have had all 3 treatments. 10) First 13 patients in Israel under HE program have had all 3 treatments. Israeli govt has approved 13 additional patients under HE program.
CV gives perfect opportunity to utilize their software for distant learning. Are they taking advantage to sell to Edu market or too busy try to promote themselves to investors in Asia?
So new launch date means they will have minimal revenue from still being in pre launch. Any indication why the delay?
Need to get current first. News will have little affect until stop sign removed.
Hoping they take this opportunity on Wednesday’s call to provide updated HE status reporting. Positive results will drive this higher, much much higher. $BCLI